Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.34 |
| ▸ | CFTR | P13569 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21735574 | 0.97 | JAK1 (0.36) | JAK1TLR7TLR8NPC1RAB9A | |
| SCHEMBL21735567 | 0.90 | JAK1 (0.39) | JAK1TLR7TLR8JAK2 | |
| SCHEMBL21735570 | 0.88 | JAK1 (0.40) | JAK1TLR7TLR8CFTRJAK2 | |
| SCHEMBL21735572 | 0.87 | JAK1 (0.38) | JAK1TLR7TLR8JAK2 | |
| SCHEMBL23917089 | 0.85 | TLR7 (0.37) | TLR7TLR8CFTR | |
| SCHEMBL23916891 | 0.85 | TLR7 (0.38) | JAK1TLR7TLR8CFTRJAK2 | |
| SCHEMBL23916900 | 0.84 | TLR7 (0.39) | TLR7TLR8 | |
| SCHEMBL23916902 | 0.83 | JAK1 (0.40) | JAK1TLR7TLR8JAK2 | |
| SCHEMBL21735565 | 0.81 | TLR7 (0.35) | JAK1TLR7TLR8JAK2 | |
| SCHEMBL21733010 | 0.81 | JAK2 (0.42) | JAK1TLR7TLR8JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317118-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2021-10-14 | — | — | US | disclosed |
| WO-2020037092-A1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317118-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | JAK1 2951/4885TLR7 236/4885TLR8 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.